DelveInsight’s, “Exosomes Pipeline Insight, 2021” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a Free Sample to know about the report- https://www.delveinsight.com/sample-request/exosomes-pipeline-insight
Exosomes are small membrane vesicles of endocytic origin that are secreted by most cells in culture and are created upon the fusion of the multivesicular body (MVB)—an intermediate endocytic compartment—with the plasma membrane. They are nano-sized vesicles capable of transferring DNAs, micro RNAs, non-coding RNAs, and lipids, with or without direct cell-to-cell contact, which represents a novel method of intracellular communication. MVB—a type of intraluminal vesicles (ILV’s)—buds inward into the endosomal lumen.
Exosomes, produced in the endosomal compartment of most eukaryotic cells, are released in the form of ILV’s in instances where the MVB fuses with the cell surface (the plasma membrane). The exosomes and other extracellular vesicles (EV’s) are present in tissues of the multicellular organisms, including biological fluids, such as blood, urine, and cerebrospinal fluid. They can also be released in vitro by the cultured cells into their growth medium.
Major Key Players of the Exosomes Pipeline report
- Direct Biologics
- Codiak BioSciences
- ExoCyte Therapeutics
- Avalon GloboCare
- United Therapeutics Corporation
- Capricor Therapeutics
- Avalon GloboCare
- Azymus Therapeutics
- Versatope Therapeutics
- Lamellar Biomedical
- Celltrion
- And many others
Exosomes Pipeline: Drugs
- LAMELLASOME IPF-NA
- exoSTING
- ET-08
- AVA 201
- Unexisome
- CAP 2003
- exoIL 12
- AVA 203
- AZ 001
- VT 105
- And many others
Exosomes Pipeline: Report
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Exosomes Pipeline: Characteristics
- The plasma membrane invagination from the endocytic vesicles.
- The second stage is the inward building of the endosomal membrane which gives rise to multivesicular bodies (MVB’s).
- The third and the last stage is when the MVB’s fuse with the plasma membrane and release the vesicular contents, which in turn forms the exosomes.
- The membrane proteins, which undergo the endosomal pathway, exhibit the same stages. Different types of lipidic molecules are known for their involvement in the exosome formation and release like phosphatidic acid and ceramides.
Exosomes Pipeline: Composition
Due to its protein and lipid content, exosomes are special, providing an additional hint for their identification. Exosomes mainly include fusion and transport proteins (annexins and flotillin), heat shock proteins (HSP70), CDís proteins (CD9, CD81), and phospholipases and other lipid-related proteins. Due to its protein and lipid content, exosomes are special, providing an additional hint for their identification. Exosomes mainly include fusion and transport proteins (annexins and flotillin), heat shock proteins (HSP70), CDís proteins (CD9, CD81), and phospholipases and other lipid-related proteins. One can use all of these proteins as positive markers.
Exosomes Pipeline: Biological Functions
Exosomes are nano-sized EVs that have impressive physiological properties and emerge through the inward budding of the late endosomal membrane called multivesicular bodies (MVBs). As MVBs are fused with the plasma membrane, exosomes are released into the extracellular environment. They can either be taken up by target cells residing in the microenvironment or transported by biological fluids to distant sites. Exosomes have a small diameter range of 40–100 nm and a density of 1.13–1.19 g/ml in sucrose solution. They can be sedimented at 100,000 g by centrifugation. Also, exosome membranes are enriched with proteins from cholesterol, sphingomyelin, ceramide and lipid raft.
Exosomes Pipeline: Emerging Drugs
- Neural exosomes (AB126): ArunA Biomedical
ArunA Biomedical’s proprietary neural exosomes cross the blood–brain barrier inherently and enable drugs and drug-combinations to naturally target cells and treat patients with a range of neurological disorders. Preclinical studies have demonstrated the therapeutic potential of these exosomes in multiple stroke models. These studies have shown that the exosomes enhance the nervous system’s self-repair mechanisms, translating into structural and functional benefits which may have improved survival, reduced infarct size, and improved mobility.
- ExoPr0: ReNeuron
Company’s CTX-derived exosomes candidate is currently in the preclinical stage and is being developed as a novel vector for delivering the third party biological drugs. ExoPr0 has demonstrated potential as both a novel therapeutic candidate as well as a drug delivery vehicle in established preclinical disease models. The company intends to devote more significant resource to the application of ExoPr0 as a vector for delivering drugs.
- exoIL-12: Codiak Biosciences
exoIL-12 is a precision-engineered exosome therapeutic candidate expressing IL-12 on the surface of the exosome by molecular fusion to Codiak’s proprietary scaffold protein, PTGRFN. Developed via Codiak’s proprietary engEx platform, exoIL-12 is designed to target T-cells and Natural Killer cells and induce systemic anti-tumor immunity. Data from Codiak’s preclinical studies suggest that when administered intratumorally, exoIL-12 is retained in the tumor microenvironment, thus resulting in potent antitumor immunity and an improved toxicity profile compared to recombinant IL-12.
Table of Content
- Introduction
- Executive Summary
- Exosomes: Overview
- Formation
- Exosomes in CNS Disease
- Exosomes in Oncology
- Exosomes in Other Diseases
- Pipeline Therapeutics
- Therapeutic Assessment
- Exosomes – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Exosomes Collaboration Deals
- Mid Stage Products (Phase I/II)
- MPCs-derived exosomes: Cellular Biomedicine Group Ltd.
- AGLE 102: Aegle Therapeutics
- Pre-clinical and Discovery Stage Products
- exoSTING: Codiak BioSciences
- AVA 201: Avalon GloboCare
- UNEX 42: United Therapeutics Corporation
- CAP 2003: Capricor Therapeutics
- AB 126: ArunA Biomedical
- Inactive Products
- Exosomes Key Companies
- Exosomes Key Products
- Exosomes- Unmet Needs
- Exosomes- Market Drivers and Barriers
- Exosomes- Future Perspectives and Conclusion
- Exosomes Analyst Views
- Exosomes Key Companies
- Appendix
What are the Exosomes Pipeline Report Highlights?
- The companies and academics are working to assess challenges and seek opportunities that could influence Exosomes R&D. The therapies under development are focused on novel approaches to treat/improve Exosomes.
- Anjarium’s Hybridosome platform, coupled with the targeting technology and proprietary manufacturing methods, is a promising technology to overcome the delivery hurdles today’s most potent RNA therapeutic candidates face.
- Therapeutic Benefits: Exosomes are directly internalized by recipient cells, which prevent a multiplicity of potential concerns associated with the administration of living cells, and exosomes have therapeutic benefits, at least equivalent to their cellular source.
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Shruti Thakur
info@delveinsight.com
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/